Postoperative hypofrActionated Radiation in Cervical and Endometrial TumouRs:Phase II Study (PARCER II) - PARCER II

Tata Memorial Centre Research Administrative Council0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•1.Eastern Cooperative Oncology Group (ECOG) performance status of =2
•2.Carcinoma of the cervix post-surgery with intermediate or high-risk features or needing adjuvant RT ± concurrent chemotherapy OR Carcinoma of the endometrium post-surgery requiring adjuvant (chemo)radiotherapy to pelvis with/without vaginal brachytherapy.

•1. Patients with macroscopic residual disease (R+ resection) post operatively
•2. Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer)
•3. Patients treated with chemotherapy for any prior malignancy at any time
•4. Patients treated with pelvic radiation previously
•5. Patients with human immunodeficiency virus infection
•6. Any preexisting medical conditions that may interfere with assessment of GU or GI toxicity
•(This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemarrhoids precluding analysis of gastro-intestinal toxicities, and urinary incontinence, recurrent urinary tract infections)

发起方

Tata Memorial Centre Research Administrative Council